PDS Biotechnology Corporation

Contributing Author

Recent Articles by PDS Biotechnology Corporation

Nov-06	PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results PDSB GlobeNewswire
Oct-30	New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting PDSB GlobeNewswire
Oct-29	PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer PDSB GlobeNewswire
Sep-18	PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1-19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population PDSB GlobeNewswire
Sep-02	PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PDSB GlobeNewswire
Aug-25	PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer PDSB GlobeNewswire
Aug-13	PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update PDSB GlobeNewswire
Aug-06	PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results PDSB GlobeNewswire
Jul-10	PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results PDSB GlobeNewswire
Jun-09	PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune HPV for the Treatment of HPV16+ HNSCC PDSB GlobeNewswire
Jun-02	PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PDSB GlobeNewswire
May-22	PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PDSB GlobeNewswire
May-20	PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase PDSB GlobeNewswire
May-14	PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update PDSB GlobeNewswire
May-09	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PDSB GlobeNewswire
May-08	PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025 Annual Meeting PDSB GlobeNewswire
May-07	PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results PDSB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.